About the Company
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AKBA News
Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
On Akebia Therapeutics Inc ( NASDAQ:AKBA) released its 8-K filing, detailing the fourth quarter and full-year financial ...
Buy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial Position
Akebia Therapeutics (AKBA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...
AKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023
AKBA stock results show that Akebia Therapeutics beat on revenue for the fourth quarter of 2023.More From InvestorPlace The ...
Analysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)
and Apogee Therapeutics, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akebia Therapeutics with a $4.33 average price target, representing a 170.6% upside.
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferri ...
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
It's been a pretty great week for Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders, with its shares surging ...
Earnings Preview For Akebia Therapeutics
Akebia Therapeutics AKBA is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement. Analysts estimate that Akebia ...
Recap: Akebia Therapeutics Q4 Earnings
Akebia Therapeutics AKBA reported its Q4 earnings results on Thursday, March 14, 2024 at 04:15 PM. Here's what investors need to know about the announcement. Akebia Therapeutics beat estimated ...
Digital medicine maker Akili slashed executive pay in 2023
Top executives at therapeutic video game maker Akili got significantly less in total compensation in 2023 compared to the ...
Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
Akero Therapeutics, Inc. (AKRO) closed the last trading session at $26.99, gaining 28.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Loading the latest forecasts...